Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C4484774!4484774!24236454     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Mol+Med 2014 ; 14 (3): 385-95 Nephropedia Template TP {{tp|p=24236454|t=2014. Novel Adjunctive Therapies for the Treatment of Tuberculosis |pdf=|usr=}}{{24236454}} gab.com Text Novel Adjunctive Therapies for the Treatment of Tuberculosis JO: Curr Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=24236454 #FOAvip Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and ?non-antimicrobial? pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field. Twit Text FOAVip Novel Adjunctive Therapies for the Treatment of Tuberculosis ????Curr Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=24236454 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24236454 #FOAvip English Wikipedia <ref>{{Cite pmid|24236454}}</ref> Novel Adjunctive Therapies for the Treatment of Tuberculosis #MMPMID24236454 Ordonez A; Maiga M; Gupta S; Weinstein E; Bishai W; Jain S Curr Mol Med 2014[Mar]; 14 (3): 385-95 PMID24236454show ga Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and ?non-antimicrobial? pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field. äNovel Adjunctive Therapies for the Treatment of Tuberculosis (epmc).pdf DeepDyve Pubget Overpricing